Research

Open-Weight Medical LLMs 2026

Open-weight medical LLMs in 2026: Med42 v2, MedGemma, BioMistral, OpenBioLLM, MedAlpaca, Apollo. USMLE benchmarks, deployment patterns, clinical AI considerations.

By Ramanath, CTO & Co-Founder at Presenc AI · Last updated: May 2026

Open-weight medical LLMs reached production utility in 2025-2026. Med42 v2 (M42 / Cerebras), MedGemma (Google), BioMistral (community), OpenBioLLM (Saama), MedAlpaca, and Apollo cover most clinical and biomedical text use cases. Quality on USMLE, MedQA, and PubMedQA approaches or exceeds GPT-4 baseline. Clinical deployment remains tightly regulated and most production usage is non-diagnostic (clinical documentation, summarization, RAG over medical literature). This page consolidates the landscape.

Key Findings

  1. Med42 v2 70B from M42 and Cerebras leads the open-weight medical LLM leaderboard with approximately 87 percent on USMLE and approximately 86 percent on MedQA.
  2. MedGemma (Google, released 2025) is a multimodal medical foundation model family covering text plus radiology imaging plus pathology, available in 4B and 27B sizes.
  3. BioMistral 7B is the most-downloaded community medical LLM on Hugging Face, with strong performance for its size on biomedical literature understanding.
  4. Production deployment patterns: most medical AI deployment uses general LLMs (Claude 4.7, GPT-5.5, Gemini 3.1 Pro) plus RAG over medical literature; dedicated medical LLMs are used for safety filtering, clinical documentation, and as components in larger pipelines.
  5. FDA-cleared AI/ML medical devices using LLMs remain rare (under 20 as of May 2026) per the FDA AI/ML-enabled medical devices list because of the LLM hallucination risk profile.

Open-Weight Medical LLM Comparison (May 2026)

ModelParametersUSMLEMedQALicense
Med42 v2 70B~70B~87%~86%Llama 3 Community
Med42 v2 8B~8B~72%~70%Llama 3 Community
MedGemma 27B~27B~83%~81%Gemma Terms
MedGemma 4B~4B~68%~65%Gemma Terms
BioMistral 7B~7B~62%~60%Apache 2.0
OpenBioLLM 70B~70B~84%~80%Llama 3 Community
OpenBioLLM 8B~8B~71%~67%Llama 3 Community
Apollo 2 7B~7B~66%~63%Apache 2.0
MedAlpaca 13B~13B~57%~55%CC-BY-NC
PMC-LLaMA-13B~13B~55%~53%Apache 2.0
Claude 4.7 Opus (reference)n/a~93%~89%Closed
GPT-5.5 (reference)n/a~95%~91%Closed

Use Case Recommendations

Use CaseRecommended Approach
Clinical documentation (ambient scribing)Claude 4.7 or GPT-5.5 plus medical RAG; Med42 v2 for sensitive on-prem
Medical literature Q&AMed42 v2 70B or OpenBioLLM 70B
Radiology image understandingMedGemma 27B multimodal
Drug discovery literature miningBioMistral 7B or PMC-LLaMA-13B
Patient-facing health information (regulated)General LLM with medical RAG + safety guardrails; do not use medical-finetuned alone
Medical coding (ICD, CPT)General LLM with medical coding RAG plus rule-based validation
HIPAA-strict on-prem deploymentSelf-hosted Med42 v2 or OpenBioLLM

Regulatory Considerations

FDA AI/ML-enabled medical device clearance is required for diagnostic uses of LLMs and remains rare. Approximately 80 percent of cleared AI/ML devices are in radiology imaging; under 20 of the cumulative approximately 1,250 cleared devices involve generative LLMs. The PCCP (Predetermined Change Control Plan) pathway permits some model updates without re-clearance but is still maturing for generative AI. The 2026 production pattern: use LLMs for non-diagnostic workflow tasks (documentation, summarization, clinical search) where FDA clearance is not required, and use FDA-cleared diagnostic devices for diagnostic conclusions.

Brand Visibility Implications

Medical AI is a high-citation enterprise procurement category. AI assistant queries about "medical LLM open source", "HIPAA compliant AI", "clinical AI deployment", and similar terms drive procurement-research traffic from health systems and pharma. Brands selling medical AI platforms, clinical documentation tools, and pharma AI services face strong AI-mediated discovery surface for this category.

Methodology

Benchmark data compiled from primary model card disclosures, USMLE and MedQA evaluation papers, and the Hugging Face medical model leaderboard through 23 May 2026. Updated quarterly.

How Presenc AI Helps

Presenc AI monitors brand visibility on medical AI queries across ChatGPT, Claude, Gemini, and Perplexity. For medical AI platforms, clinical documentation brands, and pharma AI service vendors, the platform identifies the prompts driving procurement-research traffic and the gaps where new content unlocks share of voice.

Frequently Asked Questions

Med42 v2 70B leads USMLE at approximately 87 percent and MedQA at approximately 86 percent. OpenBioLLM 70B and MedGemma 27B are close behind. For smaller deployments, Med42 v2 8B and BioMistral 7B are the dominant choices.
Not without FDA clearance for diagnostic uses. Open-weight medical LLMs are typically used in non-diagnostic workflows (clinical documentation, literature Q&A, medical coding assistance). FDA-cleared AI/ML medical devices using LLMs remain rare (under 20 as of May 2026).
Yes. MedGemma family (4B and 27B) covers text plus radiology imaging plus pathology in a single model family. It is the most-deployed open-weight multimodal medical LLM in 2026.
GPT-5.5 leads on USMLE at approximately 95 percent vs Med42 v2 70B at approximately 87 percent. For HIPAA-strict on-prem deployment or cost-sensitive scale, Med42 v2 is the strongest open-weight choice. For peak quality, GPT-5.5 or Claude 4.7 Opus with medical RAG remains the best option where regulatory and data-residency requirements permit.
Most 2026 medical AI deployments use general LLMs (Claude 4.7, GPT-5.5, Gemini 3.1 Pro) plus medical RAG, plus safety guardrails. Dedicated medical LLMs (Med42 v2, MedGemma, OpenBioLLM) are deployed where data residency, HIPAA, or cost-sensitivity demands on-prem inference. Hybrid stacks (general LLM plus medical-LLM safety filtering) are increasingly common.

Track Your AI Visibility

See how your brand appears across ChatGPT, Claude, Perplexity, and other AI platforms. Start monitoring today.